Global Urothelial Carcinoma Treatment Market Share (%), by Region, 2017
Source: Centers for Disease Control and Prevention (CDC)
On a regional basis, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
Americas is likely to dominate the urothelial carcinoma treatment market owing to the increasing prevalence of bladder cancer, increasing investment in research and development of new bladder cancer treatment. According to the American cancer society report, about 79030 cases of bladder cancer was reported in 2017 in the US.
Europe is the second largest market for the urothelial carcinoma treatment followed by Asia-Pacific. Due to growing awareness regarding early diagnosis of bladder cancer and developed healthcare infrastructure with increasing prevalence of urothelial cancer. Asia-Pacific shows the fastest growth in the market due to the low cost of R&D. India and China are expected to be the fastest growing market for bladder cancer treatment.
The Middle East and Africa has the lowest market for urothelial carcinoma treatment due to poor medical facilities and lack of technology.
Global Urothelial Carcinoma Treatment Market, by Type
Global Urothelial Carcinoma Treatment Market, by Treatment
Global Urothelial Carcinoma Treatment Market, by End-User
Global Urothelial Carcinoma Treatment Market, by Region
|Market Size||2030: Significant Value|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Types, Treatment, And End-Users|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||GlaxoSmithKline plc, Genentech, Inc., Novartis AG, Dendreon, Merck KGaA, Eisai Co., Sanofi S.A., Bristol-Myers Squibb|
|Key Market Opportunities||Investment in R&D activities to come up with new cancer treatment|
|Key Market Drivers||Growing prevalence of cancer|
Urothelial Carcinoma, also known as transitional cell carcinoma, is a cancer of the urinary bladder that can spread to other parts of the body.
Urothelial Carcinoma is expected to exhibit a strong 19.10% CAGR over the forecast period from 2022 to 2030.
Growing prevalence of cancer is the major driver for the market.
Americas hold the largest share in the global Urothelial Carcinoma Market.
Leading players in the Urothelial Carcinoma Market include Sanofi, Genentech, and Novartis, among others.